Cardiac pathology in neuronal ceroid lipofuscinoses (NCL): More than a mere co-morbidity.
Katja Rietdorf, Emily E Coode, Angela Schulz...
https://pubmed.ncbi.nlm.nih.gov/31863828Actively Recruiting
Led by Universitätsklinikum Hamburg-Eppendorf · Updated on 2021-10-29
500
Participants Needed
1
Research Sites
N/A
Total Duration
This research aims to understand the natural history and progression of Neuronal Ceroid Lipofuscinoses (NCL), also known as Batten disease, which are rare inherited neurodegenerative disorders caused by mutations in various genes. These mutations lead to progressive loss of motor skills, cognition, vision, seizures, and behavior changes. The study seeks to document symptom development and disease progression more accurately to support testing of new experimental treatments and improve scientific knowledge. Participants include patients with genetically confirmed NCL diagnoses, covering multiple gene mutations such as CLN1 through CLN14. The study collects data through medical records, patient questionnaires, and routine clinical exams focused on motor, language, cognition, seizures, vision, and behavior. A local biorepository and an international virtual biorepository are established to facilitate access to patient samples for research. Families of deceased patients with known genetic mutations may also contribute retrospective data. During participation, researchers gather clinical information over time to identify key symptoms and develop tools for rating disease progression, with follow-up lasting up to 30 years. This includes establishing well-characterized natural history cohorts to serve as controls for future therapy trials. The study also collects and stores biological samples to support international research efforts. There is no treatment involved; instead, the focus is on observation and data collection to better understand NCL diseases.
CONDITIONS
Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 30 years
Participants with genetically confirmed NCL are observed to collect natural history and clinical follow-up data to understand disease progression and key symptoms.
Periodic visits depending on individual patient assessments
Total: 1 location
1
University Medical Center Hamburg-Eppendorf
Hamburg, Germany, 20246
Actively Recruiting
M
Miriam Nickel, MD
A
Angela Schulz, MD, PhD
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
14
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Katja Rietdorf, Emily E Coode, Angela Schulz...
https://pubmed.ncbi.nlm.nih.gov/31863828Miriam Nickel, Alessandro Simonati, David Jacoby...
https://pubmed.ncbi.nlm.nih.gov/30119717Angela Schulz, Temitayo Ajayi, Nicola Specchio...
https://pubmed.ncbi.nlm.nih.gov/29688815Emily Gardner, Mitch Bailey, Angela Schulz...
https://pubmed.ncbi.nlm.nih.gov/31283065Michael Fietz, Moeenaldeen AlSayed, Derek Burke...
https://pubmed.ncbi.nlm.nih.gov/27553878Alessandro Simonati, Ruth E Williams, Nardo Nardocci...
https://pubmed.ncbi.nlm.nih.gov/28542837Anne-Hélène Lebrun, Stephan Storch, Franz Rüschendorf...
https://pubmed.ncbi.nlm.nih.gov/19309691Ruth E Williams, Heather R Adams, Martin Blohm...
https://pubmed.ncbi.nlm.nih.gov/28335910Alfried Kohlschütter, Angela Schulz, Udo Bartsch...
https://pubmed.ncbi.nlm.nih.gov/30877620U Löbel, J Sedlacik, M Nickel...
https://pubmed.ncbi.nlm.nih.gov/27231226